How Early Zugo-cel Data and Lilly Partnership Could Impact CRISPR Therapeutics (CRSP) Investors [Yahoo! Finance]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Yahoo! Finance
B-cell lymphoma and autoimmune diseases, and disclosed a new collaboration with Eli Lilly to test zugo-cel alongside pirtobrutinib. By pairing strong initial response rates and a favorable safety profile with Lilly's kinase inhibitor, CRISPR Therapeutics is broadening zugo-cel's potential role across both oncology and autoimmune indications. We'll now examine how the early zugo-cel data in aggressive B-cell lymphoma could influence CRISPR Therapeutics' longer-term investment narrative. The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. To own CRISPR Therapeutics, you need to believe that its gene-editing toolkit can convert promising science into durable, high-value products before the cash burn and competition catch up. The zugo-cel update fits neatly into that thesis: early aggressive B-cell lymphoma data and the Eli Lilly pirtobrutinib combo expand the story beyond ex
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- Is CRISPR Therapeutics Stock Yesterday's News? [Yahoo! Finance]Yahoo! Finance
- 3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics (NASDAQ:CRSP) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $80.00 price target on the stock.MarketBeat
- CRISPR Therapeutics (NASDAQ:CRSP) had its "market outperform" rating reaffirmed by analysts at Citizens Jmp. They now have a $86.00 price target on the stock.MarketBeat
- CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic MalignanciesGlobeNewswire
CRSP
Earnings
- 11/10/25 - Beat
CRSP
Sec Filings
- 12/23/25 - Form 4
- 12/22/25 - Form 4
- 12/22/25 - Form 144
- CRSP's page on the SEC website